(Q33821336)

29 July 2017

1 reference

title

Pharmacotherapy for advanced Parkinson's disease (English)

1 reference

29 July 2017

0 references

1 reference

Stacy M

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 January 2000

1 reference

29 July 2017

1 reference

29 July 2017

volume

20

1 reference

29 July 2017

issue

1 Pt 2

1 reference

29 July 2017

page(s)

8S-16S

1 reference

Current approaches in the treatment of Parkinson's disease

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.2.8S.34630

Parkinson's disease: pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.2.8S.34630

Levodopa-induced dyskinesia: review, observations, and speculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.2.8S.34630

On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.2.8S.34630

Dystonia in Parkinson's disease: clinical and pharmacological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.2.8S.34630

Induction of chorea and dystonia in parkinsonian primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.2.8S.34630

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.2.8S.34630

Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.2.8S.34630

Compensations after lesions of central dopaminergic neurons: some clinical and basic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.2.8S.34630

Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.2.8S.34630

A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.2.8S.34630

The effects of oral protein on the absorption of intraduodenal levodopa and motor performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.2.8S.34630

Cabergoline in Parkinson's disease complicated by motor fluctuations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.2.8S.34630

Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.2.8S.34630

Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.2.8S.34630

The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.2.8S.34630

Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.2.8S.34630

10.1592/PHCO.20.2.8S.34630

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference